- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Immunocore Holdings PLC (IMCR)
Immunocore Holdings PLC stock price live, this page displays NASDAQ IMCR stock exchange data. View the IMCR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Immunocore Holdings PLC real time stock price chart below.
What Is the Immunocore Holdings PLC Stock Price Today?
The Immunocore Holdings PLC stock price today is 32.10.
What Is the Stock Symbol for Immunocore Holdings PLC?
The stock symbol for Immunocore Holdings PLC is ""IMCR.""
What Stock Exchange Does Immunocore Holdings PLC Trade On?
Immunocore Holdings PLC is listed and trades on the NASDAQ stock exchange.
Is Immunocore Holdings PLC a Good Stock to Buy?
Determining whether Immunocore Holdings PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMCR quote. (ISIN: US45258D1054)
What Is the Immunocore Holdings PLC Stock Price Today?
The Immunocore Holdings PLC stock price today is 32.10.
What Is the Stock Symbol for Immunocore Holdings PLC?
The stock symbol for Immunocore Holdings PLC is ""IMCR.""
What Stock Exchange Does Immunocore Holdings PLC Trade On?
Immunocore Holdings PLC is listed and trades on the NASDAQ stock exchange.
Is Immunocore Holdings PLC a Good Stock to Buy?
Determining whether Immunocore Holdings PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the IMCR quote. (ISIN: US45258D1054)
32.10
-0.40(-1.23%)
Closed·
After Hours
32.100.00(0.00%)
·
Fair Value
An estimate of a Immunocore Holdings's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
30.99
32.62
52 wk Range
23.15
39.33
IMCR Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
IMCR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Immunocore Holdings's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
30.9932.62
52 wk Range
23.1539.33
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IMCR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Immunocore Holdings's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
62.45
Upside
+94.54%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell
Immunocore Holdings PLC Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company’s products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Immunocore Holdings PLC SWOT Analysis
Kimmtrak's Triumph | Explore Immunocore's flagship product Kimmtrak, driving financial performance with impressive European growth and meeting sales expectations globally |
Pipeline Potential | Delve into Immunocore's promising HIV treatment IMC-M113V, showing encouraging early-stage results and a favorable safety profile in clinical trials |
Market Challenges | Learn about the slowdown in US Kimmtrak sales and its impact on Immunocore's growth trajectory, alongside competitive pressures in the biotechnology secto |
Analyst Outlook | Discover varied analyst perspectives, with price targets ranging from $38 to $66, reflecting the company's potential amid clinical development risks and market uncertainties |
Immunocore Holdings PLC Earnings Call Summary for Q4/2024
- Q4 2024 EPS of -0.47 missed forecast by 23 cents; revenue slightly below expectations at $84.05 million
- Total 2024 revenue reached $310 million, up 30% YoY; KymTrak achieved 65% U.S. market penetration
- Stock fell 2.43% pre-market; company maintains strong liquidity with current ratio of 3.78
- Expanding pipeline with ongoing trials in melanoma and other areas; focus on community setting prescriptions
- Expects incremental KymTrak growth in 2025; significant developments anticipated in HIV program
Last Updated: 26/02/2025, 15:15
Read Full TranscriptCompare IMCR to Peers and Sector
Metrics to compare | IMCR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMCRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −74.6x | −1.7x | −0.5x | |
PEG Ratio | −1.15 | 0.01 | 0.00 | |
Price/Book | 4.3x | 1.1x | 2.6x | |
Price / LTM Sales | 4.8x | 11.9x | 3.3x | |
Upside (Analyst Target) | 102.5% | 276.0% | 43.5% | |
Fair Value Upside | Unlock | 40.3% | 6.9% | Unlock |
Analyst Ratings
13 Buy
3 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 62.45
(+94.54% Upside)
Earnings
Latest Release
May 07, 2025
EPS / Forecast
0.10 / -0.39
Revenue / Forecast
93.88M / 86.10M
People Also Watch
FAQ
What Stock Exchange Does Immunocore Holdings Trade On?
Immunocore Holdings is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Immunocore Holdings?
The stock symbol for Immunocore Holdings is "IMCR."
What Is the Immunocore Holdings Market Cap?
As of today, Immunocore Holdings market cap is 1.61B.
What Is Immunocore Holdings's Earnings Per Share (TTM)?
The Immunocore Holdings EPS (TTM) is -0.43.
When Is the Next Immunocore Holdings Earnings Date?
Immunocore Holdings will release its next earnings report on 04 Nov 2025.
From a Technical Analysis Perspective, Is IMCR a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Immunocore Holdings Stock Split?
Immunocore Holdings has split 0 times.
How Many Employees Does Immunocore Holdings Have?
Immunocore Holdings has 493 employees.
What is the current trading status of Immunocore Holdings (IMCR)?
As of 07 Aug 2025, Immunocore Holdings (IMCR) is trading at a price of 32.10, with a previous close of 32.10. The stock has fluctuated within a day range of 30.99 to 32.62, while its 52-week range spans from 23.15 to 39.33.
What Is Immunocore Holdings (IMCR) Price Target According to Analysts?
The average 12-month price target for Immunocore Holdings is USD62.44727, with a high estimate of USD100 and a low estimate of USD24.709. 13 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +94.54% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.